Case Report
BibTex RIS Cite

A case report of euglycemic ketoacidosis due to dapagliflozin treatment

Year 2021, Volume: 3 Issue: Supplement 1, 85 - 86, 07.03.2021
https://doi.org/10.46310/tjim.877156

Abstract

Diabetic ketoacidosis (DKA) is a leading cause of mortality and morbidity in type 2 diabetic patients. Sodium-glucose co-transporter (SGLT-2) inhibitors are a new antidiabetic treatment class that increases the renal excretion of glucose. The Food and Drug Administration issued a warning in May 2015 notifying that patients using this class of anti-diabetic drugs may develop DKA. Risk factors for DKA development among patients who take SGLT-2 inhibitors include carbohydrate intake/starvation or acute illness. In the current report, we aimed to present a case of euglycemic DKA using dapagliflozin treatment.

References

  • 1. Chao EC, Henry RR. SGLT2 inhibition--a novel strategy for diabetes treatment. Nat Rev Drug Discov 2010;9(7):551–9.
  • 2. Dhatariya KK, Umpierrez GE. Guidelines for management of diabetic ketoacidosis: time to revise? Lancet Diabetes Endocrinol 2017;5(5):321–3.
  • 3. Yu X, Zhang S, Zhang L. Newer Perspectives of Mechanisms for Euglycemic Diabetic Ketoacidosis. Int J Endocrinol 2018;2018:7074868.
  • 4. Fralick M, Schneeweiss S, Patorno E. Risk of Diabetic Ketoacidosis after Initiation of an SGLT2 Inhibitor. N Engl J Med 2017;376(23):2300–2.
  • 5. Food and Drug Administration, FDA drug safety communication: FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the bloodNovember 2019 http://www.fda.gov/Drugs/Drug.Safety/ucm446845.htm.
  • 6. Taylor SI, Blau JE, Rother KI. SGLT2 Inhibitors May Predispose to Ketoacidosis. J Clin Endocrinol Metab 2015;100(8):2849–52.
  • 7. American Diabetes Association. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2021. Diabetes Care 2021;44(Suppl 1):S111–24.
  • 8. Burke KR, Schumacher CA, Harpe SE. SGLT2 Inhibitors: A Systematic Review of Diabetic Ketoacidosis and Related Risk Factors in the Primary Literature. Pharmacotherapy 2017;37(2):187–94.
Year 2021, Volume: 3 Issue: Supplement 1, 85 - 86, 07.03.2021
https://doi.org/10.46310/tjim.877156

Abstract

References

  • 1. Chao EC, Henry RR. SGLT2 inhibition--a novel strategy for diabetes treatment. Nat Rev Drug Discov 2010;9(7):551–9.
  • 2. Dhatariya KK, Umpierrez GE. Guidelines for management of diabetic ketoacidosis: time to revise? Lancet Diabetes Endocrinol 2017;5(5):321–3.
  • 3. Yu X, Zhang S, Zhang L. Newer Perspectives of Mechanisms for Euglycemic Diabetic Ketoacidosis. Int J Endocrinol 2018;2018:7074868.
  • 4. Fralick M, Schneeweiss S, Patorno E. Risk of Diabetic Ketoacidosis after Initiation of an SGLT2 Inhibitor. N Engl J Med 2017;376(23):2300–2.
  • 5. Food and Drug Administration, FDA drug safety communication: FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the bloodNovember 2019 http://www.fda.gov/Drugs/Drug.Safety/ucm446845.htm.
  • 6. Taylor SI, Blau JE, Rother KI. SGLT2 Inhibitors May Predispose to Ketoacidosis. J Clin Endocrinol Metab 2015;100(8):2849–52.
  • 7. American Diabetes Association. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2021. Diabetes Care 2021;44(Suppl 1):S111–24.
  • 8. Burke KR, Schumacher CA, Harpe SE. SGLT2 Inhibitors: A Systematic Review of Diabetic Ketoacidosis and Related Risk Factors in the Primary Literature. Pharmacotherapy 2017;37(2):187–94.
There are 8 citations in total.

Details

Primary Language English
Subjects ​Internal Diseases
Journal Section Case Reports
Authors

Murat Çalapkulu 0000-0002-7445-2275

Muhammed Erkam Sencar 0000-0001-5581-4886

İlknur Öztürk Ünsal 0000-0003-3999-6426

Hayri Bostan 0000-0002-4957-9856

Erman Çakal 0000-0003-4455-7276

Publication Date March 7, 2021
Submission Date February 8, 2021
Acceptance Date March 6, 2021
Published in Issue Year 2021 Volume: 3 Issue: Supplement 1

Cite

EndNote Çalapkulu M, Sencar ME, Öztürk Ünsal İ, Bostan H, Çakal E (March 1, 2021) A case report of euglycemic ketoacidosis due to dapagliflozin treatment. Turkish Journal of Internal Medicine 3 Supplement 1 85–86.

e-ISSN: 2687-4245 

Turkish Journal of Internal Medicine, hosted by Turkish JournalPark ACADEMIC, is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

by-nc-nd.png
2024 -TJIM.org